Literature DB >> 16759164

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.

Patrick Y Wen1, Santosh Kesari, Jan Drappatz.   

Abstract

Recently, there has been increasing interest in the use of targeted molecular agents for the treatment of malignant gliomas. These agents are generally well tolerated but have demonstrated only modest activity. In this article, the current status of targeted molecular agents for malignant gliomas will be reviewed and strategies to improve their effectiveness will be discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16759164     DOI： 10.1586/14737140.6.5.733

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  9 in total

Review 1.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

2.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.

Authors:  Camilo E Fadul; Patrick Y Wen; Lyndon Kim; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

4.  A novel intracellular peptide derived from g1/s cyclin d2 induces cell death.

Authors:  Christiane B de Araujo; Lilian C Russo; Leandro M Castro; Fábio L Forti; Elisabete R do Monte; Vanessa Rioli; Fabio C Gozzo; Alison Colquhoun; Emer S Ferro
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

5.  Helianthin induces antiproliferative effect on human glioblastoma cells in vitro.

Authors:  Oana Alexandru; Laura Dragutescu; Ligia Tataranu; Vasile Ciubotaru; Ani Sevastre; Ada Maria Georgescu; Oana Purcaru; Suzana Danoiu; L Magnus Bäcklund; Anica Dricu
Journal:  J Neurooncol       Date:  2010-07-16       Impact factor: 4.130

6.  Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.

Authors:  Mia Carapancea; Daria Cosaceanu; Raluca Budiu; Anna Kwiecinska; Ligia Tataranu; Vasile Ciubotaru; Oana Alexandru; Monica Banita; Catalina Pisoschi; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

7.  Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis.

Authors:  Christopher L Plaisier; Sofie O'Brien; Brady Bernard; Sheila Reynolds; Zac Simon; Chad M Toledo; Yu Ding; David J Reiss; Patrick J Paddison; Nitin S Baliga
Journal:  Cell Syst       Date:  2016-07-14       Impact factor: 10.304

8.  Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.

Authors:  Daniel R Premkumar; Esther P Jane; Swetha Thambireddy; Philip A Sutera; Jonathon M Cavaleri; Ian F Pollack
Journal:  Mol Carcinog       Date:  2017-12-30       Impact factor: 4.784

9.  Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.

Authors:  Esther P Jane; Daniel R Premkumar; Jonathon M Cavaleri; Philip A Sutera; Thatchana Rajasekar; Ian F Pollack
Journal:  J Pharmacol Exp Ther       Date:  2015-11-19       Impact factor: 4.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.